Tosoh BioscienceBiomanufacturers must balance the development of new therapeutic modalities and reduce manufacturing costs while maintaining environmental responsibility. Efforts are centred on improving process robustness and efficiency and creating more flexible manufacturing facilities that can accommodate diverse biopharmaceutical products.
WACKERIf you want to successfully guard against future pandemics, you’re going to need a good plan – and the right kind of vaccine producers. WACKER and CordenPharma have been commissioned by the German government to prepare their mRNA vaccine production lines for a new pandemic.
As a Contract Development and Manufacturing Organization (CDMO), mAbxience is committed to advancing biologics production and to ensuring that patients receive life-saving treatments faster and with uncompromising quality.
DFE Pharma, a world leader in excipients, has expanded into the biopharmaceutical market with its BioHale® portfolio, specifically designed for biologics.
2024 Cytiva, Reproduced with Permission of OwnerThe biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.
Download Hamilton’s comprehensive white paper and explore what PAT (Process Analytical Technology) means in Biopharma Upstream processes. Discover cutting-edge sensor solutions to effectively monitor critical process parameters and ensure product quality and reproducibility.
APEIRON/invIOsAustria has once again come a little closer to its goal of achieving the highest research and development rate (R&D rate) in the EU. Two thirds of R&D investments are made by industry, of which around 16% are made by foreign companies. Two current examples of investments in Austria from the life sciences sector are Novartis and Ligand Pharmaceuticals.
Sino BiologicalSino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration brings together Sino Biological’s advanced protein expression and wet-lab capabilities with BioGeometry’s generative AI protein design and optimization platform. The two companies aim to enhance their joint offerings and explore high-value market opportunities globally.
Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
BioRNThe subject of impact measurement is of crucial importance for cluster organizations as they continuously aim to enhance their support to their ecosystems with ever more innovative and efficient services. Therefore, the INNAXE’s consortium has recently developed a “Toolbox for Cluster Organisations” allowing them to easily benchmark their regions and monitor the impact of their activities towards their stakeholders.